Caplin Steriles Secures FDA Approval for Generic Desmopressin Injection in $26 Million Market
Key Insights
Caplin Steriles Limited received final FDA approval for its generic Desmopressin Acetate Injection USP, covering both single-dose and multiple-dose vials for treating bleeding disorders and diabetes insipidus.
The approved product is a therapeutic equivalent to Nordic Pharma's DDAVP injection and enters a market worth approximately $26 million in annual U.S. sales according to IQVIA data.
This approval represents the 52nd ANDA approval for parent company Caplin Point Laboratories (search), strengthening its position in the U.S. injectable pharmaceutical market.
Caplin Steriles Limited, a subsidiary of Caplin Point Laboratories (search) Limited, has secured final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Desmopressin Acetate Injection USP. The approval, announced on February 28, 2026, covers both 4 mcg/mL single-dose vials and 40 mcg/10 mL (4 mcg/mL) multiple-dose vials, positioning the company to enter a significant therapeutic market.
Therapeutic Applications and Market Opportunity
Desmopressin Acetate Injection serves critical medical applications in treating haemophilia A, von Willebrand disease, and central diabetes insipidus. The medication helps manage bleeding disorders and regulate urine production in patients with these conditions.
The approved generic product represents a therapeutic equivalent version of the Reference Listed Drug (RLD) DDAVP (desmopressin acetate) Injection manufactured by Nordic Pharma Inc. According to IQVIA data, Desmopressin Acetate injection USP had U.S. sales of approximately $26 million for the 12-month period ending December 2025, representing a substantial opportunity for Caplin Steriles to expand its presence in the U.S. injectable pharmaceutical market.
Regulatory Achievement and Company Portfolio
This approval marks the 52nd ANDA approval for Caplin Point Laboratories (search), demonstrating the company's strong regulatory capabilities. Caplin Steriles Limited has developed and filed 54 ANDAs in the USA independently and with partners, achieving 52 total approvals including acquired ANDAs.
The subsidiary operates as a fast-growing sterile product manufacturing company with approvals from multiple regulatory agencies including US FDA, EU-GMP, ANVISA, and INVIMA. The company is currently working on a portfolio of 55+ simple and complex Injectable and Ophthalmic products planned for filing over the next 4 years.
Corporate Recognition and Global Presence
Caplin Point Laboratories (search) Limited operates with a unique business model focusing predominantly on emerging markets of Latin America and Africa. The parent company has achieved consistent growth in cash flows, profitability, and revenues over the past 15 years.
Notable achievements include being featured on Forbes "Asia's 200 Best Under a Billion" list for 7 times in the last 10 years, receiving "The Emerging Company of 2018" award from Economic Times, and the "Business Excellence Award for 2019" from Economic Times.
The company maintains a diversified geographic presence with multiple product approvals in non-US markets including Australia, Canada, Mexico, Chile, UAE, Hong Kong, Malaysia, South Africa, and Saudi Arabia. The corporate structure also includes Caplin One Labs Limited (COL), another subsidiary operating an oncology unit in Kakkalur, which holds 5 approved ANDAs for Injectable and Ophthalmic products.